A Phase Ib Dose-Escalation Study of TRC105 in Combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma
ID Number 14-0091Principal Investigator(s)
Robert G Maki
Department(s) or Division(s)
Hematology and Medical Oncology
To evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose pazopanib in patients with advanced soft tissue sarcoma.
Recruiting Patients: Yes